Vise Technologies Inc. Boosts Stake in Merck & Co., Inc. $MRK

Vise Technologies Inc. raised its position in Merck & Co., Inc. (NYSE:MRK) by 50.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 110,677 shares of the company’s stock after purchasing an additional 37,158 shares during the period. Vise Technologies Inc.’s holdings in Merck & Co., Inc. were worth $11,650,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. purchased a new stake in Merck & Co., Inc. in the 4th quarter valued at about $25,000. High Note Wealth LLC increased its stake in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the last quarter. Tucker Asset Management LLC purchased a new stake in Merck & Co., Inc. in the 4th quarter valued at about $34,000. Entrust Financial LLC purchased a new stake in Merck & Co., Inc. in the 4th quarter valued at about $37,000. Finally, United Financial Planning Group LLC purchased a new stake in Merck & Co., Inc. in the 3rd quarter valued at about $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on MRK. Barclays started coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective for the company. JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday, April 6th. Guggenheim raised their price target on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research note on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. Trading Up 4.8%

Shares of MRK stock opened at $120.23 on Friday. The company has a 50 day moving average of $116.52 and a 200-day moving average of $112.32. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.14. The firm has a market cap of $296.95 billion, a P/E ratio of 33.87, a PEG ratio of 2.58 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter last year, the business posted $2.22 EPS. Merck & Co., Inc.’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.